Propofol-ketamine combination therapy for effective control of super-refractory status epilepticus

Vivek Sabharwal, Eugene Ramsay, Raisa Martinez, Rachel Shumate, Fawad Khan, Hina Dave, Ifeanyi Iwuchukwu, Harold McGrade

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


Retrospective analysis was conducted of patients with SRSE who were treated simultaneously with propofol and ketamine. Sixty-seven patients were identified from 2012 to 2015, and outcomes documented were resolution and mortality. The duration of combined ketamine and propofol use ranged from 1 to 28 days (mean - 3.6 days). Infusion rates ranged up to 145 and 175 mcg/kg/min. Vasopressors were used in 53 patients (79%), and were given within the first 5 days of the ICU admission in 48 (91%) patients. The overall SRSE resolution rate was 91%, and the overall mortality including patients with anoxic brain injury was 39%. Of the 13 patients with SRSE as a result of anoxic brain injury, SRSE was controlled in 5 (56%). The primary determinant of mortality was family withdrawing care related to the presence of severe medical/neurological diseases.

Original languageEnglish (US)
Pages (from-to)264-266
Number of pages3
JournalEpilepsy and Behavior
StatePublished - Nov 1 2015


  • Anesthetic agents
  • Ketamine
  • Mortality
  • Propofol
  • Seizure control
  • Super-refractory status epilepticus
  • Treatment

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience


Dive into the research topics of 'Propofol-ketamine combination therapy for effective control of super-refractory status epilepticus'. Together they form a unique fingerprint.

Cite this